Safety and Side Effects of Rifampin versus Isoniazid in Children | Zendy

Thierno Diallo | Zendy; Mèli Adjobimey | Zendy; Rovina Ruslami | Zendy; Anete Trajman | Zendy; Oumou Bah Sow | Zendy; Joseph Obeng Baah | Zendy; Guy B. Marks | Zendy; Richard Long | Zendy; Kevin Elwood | Zendy; David Zielinski | Zendy; M. Gninafon | Zendy; Diah Asri Wulandari | Zendy; Lika Apriani | Zendy; Chantal Valiquette | Zendy; Federica Fregonese | Zendy; Karen Hornby | Zendy; Peizhi Li | Zendy; Philip C. Hill | Zendy; Kevin Schwartzman | Zendy; Andrea Benedetti | Zendy; Dick Menzies | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Side Effects of Rifampin versus Isoniazid in Children

Author(s) -

Thierno Diallo,

Mèli Adjobimey,

Rovina Ruslami,

Anete Trajman,

Oumou Bah Sow,

Joseph Obeng Baah,

Guy B. Marks,

Richard Long,

Kevin Elwood,

David Zielinski,

M. Gninafon,

Diah Asri Wulandari,

Lika Apriani,

Chantal Valiquette,

Federica Fregonese,

Karen Hornby,

Peizhi Li,

Philip C. Hill,

Kevin Schwartzman,

Andrea Benedetti,

Dick Menzies

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1714284

Subject(s) - isoniazid , side effect (computer science) , medicine , tuberculosis , computer science , programming language , pathology

The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug. In adults, treatment with 4 months of rifampin has been shown to be safer and to have higher completion rates than 9 months of isoniazid.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research